Loading organizations...
§ Private Profile · Boise, ID, USA
Venture capital firm investing in growth-stage technology companies with flexible capital and strategic guidance.
Key people at GSquare Companies.
GSquare Companies was founded in 2005 by Garrett Goldberg (Founder; Managing Member).
G Squared is a global venture capital firm, founded in 2011 by Larry Aschebrook, who serves as its Managing Partner. Headquartered in Chicago, USA, with additional offices in San Francisco and Zurich, the firm partners with promising growth-stage technology companies. It provides flexible capital, strategic guidance, and extensive networks to help scale businesses effectively towards market leadership across key sectors such as software-as-a-service, marketplaces, mobility, new media, and financial technology. With a team of 107 employees, G Squared actively seeks out and supports innovative companies poised for significant and sustainable global expansion. Its leadership team, including Jesse Davis, Spencer McLeod, Arthur Hong (Partner & Head of G Squared Ascend), and Christopher Claassen, collectively drives its investment strategy and maintains global offices for effective deal sourcing and support.
GSquare Companies was founded in 2005 by Garrett Goldberg (Founder; Managing Member).
Key people at GSquare Companies.
G Square (also stylized as G Squared in some contexts) is a London-based private equity firm founded in 2008, specializing in mid-market healthcare companies across Europe with high-growth potential. The firm invests across four key segments—Medical Products, Healthcare IT, Healthcare Services, and Services to the Pharma Industry—employing a "buy and build" strategy with strong add-on acquisitions to drive proactive value creation.[3][5] With deep sector expertise, a team of professionals boasting years of combined relevant experience, and assets under management supporting multiple closed funds, G Square focuses on innovation-driven growth in a regulated, high-return industry.[3][5]
G Square was established in 2008 in London at 24 Savile Row, Mayfair, as a dedicated pan-European healthcare private equity investor targeting mid-market companies.[2][3][5] The firm's evolution centers on leveraging specialized sector knowledge and operational expertise from its team of highly skilled professionals across multiple nationalities and languages, enabling strategic identification and management of investments.[3] Key figures include investment professionals like Senior Associates Caroline Bouyer and Firas Jedidi, Private Equity Associate Jake Frame, and Investment Manager Loic Taieb, who bring financial acumen and industry depth.[5] Over 15+ years, G Square has built a track record of deals completed, portfolio add-ons, and funds closed (six to date, with recent ones in 2023 and 2022), solidifying its focus on healthcare's "colossal" regulatory and diverse European landscape for outsized returns.[3][5]
(Note: Search results distinguish this from G Squared, a separate 2011-founded VC firm in North America/Europe focused on tech growth-stage companies like Brex and Toast; the query aligns more closely with G Square's healthcare PE profile, but investors should verify entity specifics.[1][4])
G Square rides the wave of Europe's healthcare transformation, where regulatory complexity and aging populations create "colossal" opportunities for mid-market innovators in IT, services, and pharma-adjacent tech.[3][5] Timing is ideal amid post-pandemic digitization and M&A acceleration, with market forces like rising demand for specialized healthcare solutions favoring buy-and-build models over fragmented investments.[3] The firm influences the ecosystem by enabling scale-ups through add-ons, fostering consolidation in a diverse region, and attracting institutional capital like NEST's growth equity mandates—positioning healthcare PE as a high-return alternative to pure tech plays.[5]
G Square is primed for expansion with recent fund closes (e.g., Nov 2025) and ongoing European healthcare consolidation, potentially amplifying its buy-and-build playbook amid AI-driven medtech and telehealth booms.[3][5] Trends like regulatory tailwinds and cross-border M&A will shape its path, evolving its influence from mid-market specialist to broader ecosystem shaper—much like how it started by challenging fragmented healthcare with focused, high-potential bets. Investors eyeing superior returns in a resilient sector should watch its next deals closely.[5]
